Halozyme Therapeutics 以 $750M 預付款收購 Elektrofi

Halozyme Therapeutics 已簽署合併協議及計劃，以 $750 million 現金預付款收購 Elektrofi，另加最高三筆各 $50 million 的里程碑付款，視產品監管批准而定。此收購須符合包括反壟斷審查在內的慣例成交條件。

關鍵事實

申報時間: 2025年10月3日下午08:51
事件: 其他
方向: 中性
公司: HALOHalozyme
來源: SEC 8-K
可信度: 有出處

來源摘錄

8-K false 0001159036 0001159036 2025-09-30 2025-09-30 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 30, 2025 HALOZYME THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Commission File Number 001-32335 Delaware 88-0488686 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 12390 El Camino Real San Diego California 92130 (Address of principal executive offices) (Zip Code) (858) 794-8889 (Registrant’s telephone number, including area code) Not Applicable (Former name or former address, if changed since last report) Check the ap

SEC 8-K